This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Investors Should Buy Exact Sciences (EXAS) Stock
by Zacks Equity Research
Investors are optimistic about Exact Sciences (EXAS) on continued strength across the Screening and Precision Oncology businesses.
Strength Seen in Exact Sciences (EXAS): Can Its 24.7% Jump Turn into More Strength?
by Zacks Equity Research
Exact Sciences (EXAS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Is Bionano Genomics (BNGO) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Bionano Genomics, Inc. (BNGO) and Exact Sciences (EXAS) have performed compared to their sector so far this year.
3 Reasons to Retain Surmodics (SRDX) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its solid prospects in the thrombectomy business.
3 Hot Mid-Caps During a Cold December
by Derek Lewis
Despite the market's cold performance in December, these three stocks have remained hot, snapping the bearish trend. Their earnings outlooks suggest even more upside in 2023.
3 Reasons to Retain Nevro (NVRO) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Nevro (NVRO), owing to its R&D edge.
3 Reasons to Retain Glaukos (GKOS) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Glaukos (GKOS) on the back of continued strength in its flagship iStent.
3 Reasons to Retain OPKO Health (OPK) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about OPKO Health (OPK) owing to its potential in RAYALDEE.
3 Reasons to Retain Inogen (INGN) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Inogen (INGN) on its potential in the POC space and a strong product portfolio.
McKesson (MCK) Announces Availability of FDA-Accepted Drug
by Zacks Equity Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for PEComa.
3 Reasons to Retain Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Here's Why You Should Retain NextGen (NXGN) Stock for Now
by Zacks Equity Research
NextGen's (NXGN) strong product portfolio and continued demand for its solutions raise optimism about the stock.
McKesson (MCK) Announces Availability of FDA-Approved Drug
by Zacks Equity Research
The availability of FDA-approved drug via McKesson's (MCK) independent specialty pharmacy is expected to give patients more treatment options for AML.
Here's Why You Should Retain Abbott (ABT) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its Diabetes business and product launches.
QuidelOrtho's (QDEL) Myocardial Infarction Test Cleared in Canada
by Zacks Equity Research
QuidelOrtho's (QDEL) TriageTrue hsTnl Test is to be used to diagnose myocardial infarction following Health Canada's approval.
QuidelOrtho's (QDEL) Latest JV to Boost Footprint in China
by Zacks Equity Research
QuidelOrtho's (QDEL) new JV will likely translate into a faster time-to-market and a more compelling menu for VITROS assays in support of its growth strategy in China and beyond.
Exact Sciences (EXAS) Crossed Above the 20-Day Moving Average: What That Means for Investors
by Zacks Equity Research
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Exact Sciences (EXAS) Crossed Above the 200-Day Moving Average: What That Means for Investors
by Zacks Equity Research
Should investors be excited or worried when a stock crosses above the 200-day simple moving average?
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 34%
by Zacks Equity Research
The consensus price target hints at a 34.5% upside potential for Exact Sciences (EXAS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Exact Sciences (EXAS) Just Reclaimed the 20-Day Moving Average
by Zacks Equity Research
Good things could be on the horizon when a stock surpasses the 20-day simple moving average. How should investors react?
Wall Street Analysts Think Exact Sciences (EXAS) Could Surge 44%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 43.9% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 85%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Exact Sciences (EXAS) points to an 84.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Exact Sciences (EXAS) Q3 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Exact Sciences (EXAS) registers robust revenues from the Screening and Precision Oncology segments in Q3.
Exact Sciences (EXAS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exact Sciences (EXAS) delivered earnings and revenue surprises of 23.64% and 4.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Mirati (MRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Mirati (MRTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.